Can a drug tame excess cortisol? new trial tests metyrapone

NCT ID NCT06106295

Ongoing Disease control Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase 2 trial tests whether metyrapone, a drug that lowers cortisol production, is safe and effective for people with mild autonomous cortisol secretion (MACS). About 30 participants will take the drug for a period, and researchers will track side effects and cortisol levels. The goal is to see if metyrapone can help manage this hormonal condition.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Metyrapone
What this could lead to: If successful, this could point toward a treatment to control cortisol levels in patients with MACS, potentially reducing related health risks.
What could go wrong: This is a small, early-phase trial with only 30 participants, so results may not apply broadly. The drug may cause side effects or fail to show clear benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTONOMOUS CORTISOL SECRETION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ACTH-independent Cushing syndrome congenital adrenal hyperplasia Cushing syndrome ectopic ACTH secretion syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AUTONOMOUS CORTISOL SECRETION MILD AUTONOMOUS CORTISOL SECRETION (MACS)

Contacts and locations

Locations

Mayo Clinic Minnesota

Rochester, Minnesota, 55905, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.